| CAT # | Product Name | Description |
| CPDA601859 | Vorolanib; CM-082; X-82 | Vorolanib (CM082) is an orally active and effective VEGFR/PDGFR inhibitor. |
| CPDA601975 | AZD0022 | AZD0022 is a selective KRASG12D inhibitor with oral activity. |
| CPDA602001 | GSK4418959; IDE275 | GSK4418959 (IDE275) is a non covalent, reversible, selective, and orally active WRN helicase inhibitor. |
| CPDA602002 | RMC-5127 | RMC-5127 is a mutation selective triple complex RASG12V inhibitor with oral activity and brain permeability. |
| CPDA602003 | BMS-986449 | BMS-986449 is a CELMoD molecular glue and a degradation agent for IKZF2/IKZF4. |
| CPDA602013 | RO7656594; GDC-2992 | GDC-2992 (Compound 28A) is an orally active androgen receptor (AR) degrader. |
| CPDA602004 | AMG 410 | AMG410 is a non covalent selective pan KRAS inhibitor. |
| CPDP802326 | Topoisomerase I inhibitor 8 | Topoisomerase I inhibitor 8 is a potent Topoisomerase I inhibitor. |
| CPDD2004 | CU CPT 9a | CU-CPT-9a is a specific antagonist of TLR8. |
| CPD1221 | Revefenacin; TD 4208; GSK1160724; Yupelri | Revefenacin (TD-4208; GSK1160724) is a potent mAChR antagonist; has a high affinity on M3 receptor with a Ki of 0.18 nM |
| CPD113186 | Zasocitinib; NDI 034858; TAK 279 | Zasociatinib (NDI-034858) is a Tyk2 inhibitor that targets the JH2 domain of Tyk2. |
| CPD111676 | KSQ4279; RO7623066 | KSQ-4279 (USP1-IN-1) is an effective, first-class, and highly selective USP1 inhibitor. |
| CPD111067 | navlimetostatum; navlimetostat; MRTX 1719; BMS ... | MRTX-1719 is an effective, orally active, and selective PRMT5 • MTA complex inhibitor. |
| CPD108261 | Pirtobrutinib; LOXO 305; LY 3527727 | Pirtobrutinib (LOXO-305) is a highly selective and non covalent next-generation BTK inhibitor that can inhibit various BTK C481 substitution mutations. |
| CPD2807 | BAY 293 | BAY-293 is a potent SOS1 inhibitor that blocks RAS activation via disruption of the RAS-SOS1 interaction. BAY-293) selectively inhibits the KRAS-SOS1 interaction with an IC50 of 21 nM and is a valuable chemical probe for future investigations. |
| CPD100482 | BAY 985 | BAY-985 is an efficient, orally active, ATP competitive, selective dual inhibitor of TBK1 and IKK ε. |
| CPD100212 | Olinciguat; IW 1701 | Olinciguat (IW-1701) is an orally administered guanylate cyclase (sGC) stimulant. |
| CPD1213 | Elimusertib; BAY 1895344 | BAY-1895344 is a selective ATR (ataxia-telangiectasia and Rad3 related protein) inhibitor that inhibits proliferation of a broad spectrum of human tumor cell lines (median IC50 = 78 nM). |
| CPDM400308 | methyl 4-((tert-butoxycarbonyl)(prop-2-yn-1-yl)... | |
| CPD102238 | ML 265; CID 44246499; NCGC 00186528; TEPP 46 | TEPP-46 (ML-265) is an effective and selective activator of pyruvate kinase M2 (PKM2). |
| CPD114728 | 1-Azetidinesulfonamide(9CI) | |
| CPD100166 | Omaveloxolone; RTA 408 | Omaveloxolone (RTA 408) is an antioxidant inflammatory modulator (AIM) that activates Nrf2 and inhibits nitric oxide (NO). |
| CPD106620 | Tuxobertinib; BDTX-189 | BDTX-189 is an orally bioavailable, irreversible, selective, small-molecule inhibitor of certain oncogenic driver, allosteric mutations of the ErbB receptor tyrosine kinases epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/neu or ErbB2), including extracellular domain allosteric mutations of HER2, and EGFR and HER2 exon 20 insertion mutations, with potential antineoplastic activity. BDTX-189 selectively binds to and inhibits these allosteric ErbB mutants while sparing wild-type EGFR, which may result in the selective inhibition of cellular proliferation and angiogenesis in tumor cells and tumors expressing these allosteric ErbB mutations. |
| CPD108485 | Bavdegalutamide; ARV 110 | Bavdegalutamide, also known as ARV-110, is a first-in-class PROTAC that effectively targets the wild type Androgen Receptor (AR) and certain genomic alterations of the AR (amplification, T878A, H875Y, F877L, M895V, but not L702H or AR-V7) for degradation in both enzalutamide sensitive and resistant preclinical models. ARV-110 showed promising anti-tumor activity in heavily pretreated men with metastatic castration-resistant prostate cancer (mCRPC). |
| CPD1841 | Resmetirom; MGL3196; VIA 3196 | Resmetirom, or MGL-3196, shows outstanding safety in a rat heart model and is efficacious in a preclinical model at doses that showed no impact on the central thyroid axis. |
| CPD100419 | Ropotrectinib; TPX 0005 | Repotrecinib (TPX-0005) is an effective inhibitor of ROS1 (IC50=0.07 nM) and TRK (IC50=0.83/0.05/0.1 nM for TRKA/B/C). |
| CPD1212 | Avapritinib; BLU 285 | BLU-285 is a potent and selective exon 17 mutant KIT kinase inhibitor with IC50 of 0.27 nM for KIT D816V. |
| CPD100389 | (4-(4-Methylthiazol-5-yl)phenyl)methanamine hyd... | |
| CPD1153 | ND-646中间体; (R)-2-(2-methoxyphenyl)-2-((tetra... | |
| CPDD1230 | Verucerfont; GSK 561679; GSK 561679A; NBI 77860 | Verucerfont, also known as GSK561679 and NBI77860, is a CRF-1 antagonist. Verucerfont blocks the CRH-1 receptor, and so reduces ACTH release following chronic stress. |